Navigation Links
Target for lung cancer chemoprevention identified
Date:4/2/2011

ORLANDO, Fla. Scientists have identified a biomarker for measuring the success of lung cancer chemoprevention, an emerging frontier in the fight against this disease that has long been stymied by a lack of measureable outcomes. These study results were presented at the AACR 102nd Annual Meeting 2011, held April 2-6.

Paul Bunn, M.D., executive director of the International Association for the Study of Lung Cancer and the James Dudley endowed professor of lung cancer research at the University of Colorado Cancer Center at the University of Colorado School of Medicine, said measurements of endobronchial dysplasia, abnormal cell development that can lead to lung cancer, could predict how well a chemoprevention agent is working.

Bunn presented updated results of a study that tested the effect of oral iloprost on the improvement on endobronchial dysplasia in 152 former smokers. As smoking cessation messages take hold and quit rates increase, former smokers are still at greater risk for lung cancer than the general population.

"We told people to quit smoking and they did, but half of our lung cancer cases in the United States are coming from people who are former smokers," he said. "We need to work on ways to repair their lungs through chemoprevention."

Bunn analyzed the effect of iloprost among those who had endobronchial dysplasia at enrollment, and found a significant difference in prevalence of endobronchial dysplasia. Moreover, when they analyzed the effect of iloprost on Ki-67, a measure of cell proliferation, the difference was not significant.

This is an important advancement for the chemoprevention field, Bunn said, because it shows that they can test agents, like iloprost, and measure the effect on endobronchial dysplasia as an outcome. Chemoprevention is a goal for cancer researchers, and many of them liken the idea to heart disease prevention with statins, a major public health advance of the past 50 years.

"The challenge is there has been no real equivalent to cholesterol with cancer. This study shows that endobronchial dysplasia could play that role," he said.

This abstract will be presented at an AACR press conference on Saturday, April 2 at 10:00 a.m. ET in room W313 of the Orange County Convention Center. Reporters who cannot attend in person can dial in using the following information:

  • U.S. & Canada: (888) 647-7462
  • International: (201) 604-0169
  • Access Code: 244078


'/>"/>

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Related biology news :

1. Short rotation energy crops could help meet UKs renewable energy targets
2. Study identifies promising target for AIDS vaccine
3. HIV protein unveils vaccine target
4. New research tool targets microRNA expression in zebrafish
5. Insight into parasite family planning could help target malaria
6. Method reveals new view of human nerve cells, opening door to potential drug targets
7. Cancer-related pathways reveal potential treatment target for congenital heart disease
8. U of Alberta researcher discovers potential cancer therapy target
9. Research identifies drug target for prion diseases, mad cow
10. Viral evasion gene reveals new targets for eliminating chronic infections
11. A new drug target in atherosclerosis: The anaphylatoxin C5a
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2017)... DENVER , Feb. 6, 2017 ... national security are driving border authorities to continue ... Acuity reports there are 2143 Automated Border Control ... Kiosks currently deployed at more than 163 ports ... between 2013 to 2016 achieving a combined CAGR ...
(Date:2/2/2017)... , Feb. 2, 2017  EyeLock LLC, a market ... new white paper " What You Should Know About ... of ensuring user authenticity is a growing concern. In ... of users. However, traditional authentication schemes such as username/password ... Biometric authentication offers an elegant solution to the ...
(Date:1/30/2017)... 30, 2017   Invitae Corporation (NYSE: ... information companies, today announced that it will report its ... 2017 guidance on Monday, February 13, 2017, and Invitae,s ... at 4:45 p.m. Eastern / 1:45 p.m. Pacific. ... briefly review financial results, guidance, and recent developments and ...
Breaking Biology News(10 mins):
(Date:2/22/2017)... Fort Washington, PA (PRWEB) , ... ... ... The Omnia-Prova Education Collaborative (TOPEC), the leading medical education provider of ... Accreditation with Commendation by the Accreditation Council for Continuing Medical Education (ACCME). ...
(Date:2/22/2017)... Dublin - Research ... Crop Protection (Bio-Pesticide) Market-By Type, By Application, By End User, By ... offering. ... Biological Crop Protection Market is forecasted to grow at a CAGR ... biopesticide or biological crop protection market is driven by the surging ...
(Date:2/22/2017)... ... February 22, 2017 , ... Pharma and biotech ... as European director. Operating from Pennside’s Zurich headquarters, Pennside Partners, GmbH, Mr. Perkins ... Pennside after more than a decade with leading market research firm, GfK. He ...
(Date:2/21/2017)... - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQX: ... months ended December 31, 2016. SQI is ... company that develops and commercializes proprietary technologies and products for ... ... milestones achieved in fiscal 2016," said Andrew Morris , ...
Breaking Biology Technology: